

Special Issue

Innovative Concepts for Pharmacological Treatment of Cardiac Arrhythmias

Message from the Guest Editors

I would like to inform you that the *Pharmaceuticals* Special Issue “Innovative Concepts for Pharmacological Treatment of Cardiac Arrhythmia” is now accepting manuscripts for publication. Pharmacological treatment of cardiac arrhythmias still represents a challenge, as the number of available antiarrhythmic agents is limited to a few compounds. In particular, in the presence of chronic heart failure, antiarrhythmic drug therapy is mainly limited to amiodarone. Therefore, development of new compounds as well as identification of antiarrhythmic properties of non-cardiovascular drugs is an important topic for future development of cardiovascular therapies. Contributions to this issue include submission of original articles, review, short communications, and editorials.

Guest Editors

Prof. Dr. Gerrit Frommeyer

Department of Cardiology II (Electrophysiology), University Hospital Münster, Münster, Germany

Dr. Christian Ellermann

Department of Cardiology II - Electrophysiology, University Hospital Münster, Münster, Germany

Deadline for manuscript submissions

closed (29 October 2021)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 5.7
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/61909

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 5.7
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)